Astellas Pharma's emissions reduction targets for 2030 approved by SBTi
The Japanese firm’s climate goals are thus in line with the Paris Agreement.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Japanese pharmaceutical firm Astellas Pharma’s green ambitions have been approved by the Science Based Targets initiative (SBTi), which ensures that companies’ climate goals are in line with the Paris Agreement.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
